Medical microbiology

OpGen Data Predicting Phenotypic Antimicrobial Susceptibility Published in Diagnostic Microbiology & Infectious Disease Journal

Retrieved on: 
월요일, 3월 23, 2020
Branches of biology, Biology, Biotechnology, Applied microbiology, Clinical pathology, Emerging technologies, Microbiology, Whole genome sequencing, Medical microbiology, Molecular diagnostics, Diagnostic microbiology, Infectious disease

The findings were published in Diagnostic Microbiology & Infectious Disease, a peer-reviewed scientific journal providing the latest developments inclinical microbiologyand the diagnosis and treatment ofinfectious diseases.

Key Points: 
  • The findings were published in Diagnostic Microbiology & Infectious Disease, a peer-reviewed scientific journal providing the latest developments inclinical microbiologyand the diagnosis and treatment ofinfectious diseases.
  • The manuscript showcases the use of core genome multi locus sequence typing (cgMLST) and whole genome sequencing (WGS) data, analyzed by OpGens Acuitas Lighthouse Software to predict phenotypic antimicrobial susceptibility (AST).
  • For more information on Diagnostic Microbiology & Infectious Disease, or to access the latest issue, please click here.
  • OpGen, Inc.is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease.

ECCMID 2020 Alert: Selux Diagnostics Hosting Integrated Symposium at 30th European Congress of Clinical Microbiology & Infectious Diseases

Retrieved on: 
화요일, 2월 18, 2020
Branches of biology, Articles, Biology, Clinical pathology, Antimicrobial resistance, Evolutionary biology, Pharmaceuticals policy, Veterinary medicine, Pathology, Medical microbiology, Infection, Molecular diagnostics

BOSTON, Feb. 18, 2020 /PRNewswire/ -- Selux Diagnostics, Inc. , which is leading a new era in personalized medicine to treat superbug infections and combat antimicrobial resistance, today announced it will host an integrated symposium on aspects that impact antimicrobial resistance, rapid diagnostics and clinical care at this spring's 2020 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Paris, France.

Key Points: 
  • BOSTON, Feb. 18, 2020 /PRNewswire/ -- Selux Diagnostics, Inc. , which is leading a new era in personalized medicine to treat superbug infections and combat antimicrobial resistance, today announced it will host an integrated symposium on aspects that impact antimicrobial resistance, rapid diagnostics and clinical care at this spring's 2020 European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) in Paris, France.
  • Advances and Challenges in Rapid Diagnostics" will take place at ECCMID on Saturday, April 18, 2020 from 13:30 - 15:30 Central European Time (CET).
  • Professor of Medicine and Pathology and Laboratory Medicine, Rutgers Robert Wood Johnson Medical School
    Laboratory Service, Division of Infectious Diseases and Laboratory Medicine, Geneva University Hospitals
    Chief Technology Officer and Co-Founder, Selux Diagnostics, Inc.
    All ECCMID 2020 integrated symposia are open to all ECCMID delegates.
  • Learn more about Selux Diagnostics Integrated Symposium at ECCMID 2020 by visiting SeluxDX.com/Event/ECCMID2020 .

Global Microbiology Testing/Clinical Microbiology Market Analysis, Trends, and Forecasts Report 2019-2025 - ResearchAndMarkets.com

Retrieved on: 
목요일, 12월 19, 2019
Biotechnology, Health, Science, Research, Clinical trials, Branches of biology, Medical specialties, Microbiology, Applied microbiology, Clinical pathology, Medical microbiology, Pathology

The "Microbiology Testing/Clinical Microbiology - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Microbiology Testing/Clinical Microbiology - Market Analysis, Trends, and Forecasts" report has been added to ResearchAndMarkets.com's offering.
  • The Microbiology Testing/Clinical Microbiology market worldwide is projected to grow by US$1.8 Billion, driven by a compounded growth of 6.1%.
  • Instruments, one of the segments analyzed and sized in this study, displays the potential to grow at over 5.8%.
  • Poised to reach over US$1.6 Billion by the year 2025, Instruments will bring in healthy gains adding significant momentum to global growth.

COPAN Continues to Make Great Strides in Advancing Artificial Intelligence (A.I.) and Digital Plate Reading for Microbiology

Retrieved on: 
수요일, 10월 23, 2019
Branches of biology, Academic disciplines, Applied microbiology, Pathology, Clinical pathology, Microbiology, American Society for Microbiology, Medical microbiology, Artificial intelligence

MURRIETA, Calif., Oct. 23, 2019 /PRNewswire/ -- COPAN continues to innovate and is leading the field of Artificial Intelligence (A.I.)

Key Points: 
  • MURRIETA, Calif., Oct. 23, 2019 /PRNewswire/ -- COPAN continues to innovate and is leading the field of Artificial Intelligence (A.I.)
  • and digital culture plate reading in clinical Microbiology.
  • It reflects the advancements in Artificial Intelligence technology occurring in Microbiology laboratories and the way they are impacting laboratory medicine favorably.
  • in Microbiology increasing, COPAN is excited to support a new American Society for Microbiology (ASM) webinar series titled "Artificial Intelligence: Applications for the Clinical Microbiology Laboratory of Today."

Specific Diagnostics Receives Investment from Telegraph Hill Partners to Commercialize Critical Drug Susceptibility Technology for Clinical Microbiology Labs

Retrieved on: 
금요일, 9월 6, 2019
Branches of biology, Medical specialties, Pathology, Microbiology, Antibiotic sensitivity, Antibiotics, Medical microbiology, Susceptibility

The funding will support the commercialization of Specific's Reveal platform, which will provide a rapid, accurate antibiotic susceptibility test critical to the treatment of deadly drug resistant infections.

Key Points: 
  • The funding will support the commercialization of Specific's Reveal platform, which will provide a rapid, accurate antibiotic susceptibility test critical to the treatment of deadly drug resistant infections.
  • Specific's system provides antibiotic susceptibility results in hours instead of days using a labor- saving bench top instrument and cost-effective proprietary assay consumable.
  • Specific will now progress to clinical studies and prepare Reveal for the market, both in Europe and the United States, bringing clinical microbiology laboratories a low-cost, high-throughput susceptibility test for time-sensitive, life-threatening infections.
  • "We look forward to partnering with Telegraph Hill to take Specific into its next phase of development.

Bruker Announces Further Portfolio Expansion for Microbial Identification, Infection Control and Molecular Diagnostics of Infectious Diseases

Retrieved on: 
월요일, 4월 15, 2019
Branches of biology, Medical specialties, Medicine, Epidemiology, Microbiology, Infection, Medical microbiology, Molecular diagnostics

AMSTERDAM, April 15, 2019 /PRNewswire/ --At the European Congress of Clinical Microbiology and Infectious Diseases ( www.eccmid.org ), Bruker announces new assays, software and library extensions for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines for microbial identification, infection control and molecular diagnostics of infectious diseases.

Key Points: 
  • AMSTERDAM, April 15, 2019 /PRNewswire/ --At the European Congress of Clinical Microbiology and Infectious Diseases ( www.eccmid.org ), Bruker announces new assays, software and library extensions for its MALDI Biotyper, IR Biotyper and Fluorocycler XT product lines for microbial identification, infection control and molecular diagnostics of infectious diseases.
  • With the modular MBT bioinformatics architecture any new isolates of interest can be added for further learning and expansion of this 'gold standard' fast microbial ID system.
  • The major benefits are the fast turn-around-times (TAT) that are required to provide actionable results for timely infection control decisions.
  • Bruker is enabling scientists to make breakthrough discoveries and develop new applications that improve the quality of human life.

Arc Bio Unveils its Galileo™ Pathogen Solution: A Fully Integrated NGS-based Metagenomics Platform with a Revolutionized Design for Pathogen Detection

Retrieved on: 
목요일, 4월 11, 2019
Branches of biology, Medical specialties, Biology, Biocides, Infectious diseases, Applied microbiology, Clinical pathology, Medical microbiology, Pathology, Pathogen, Antimicrobial resistance, Antiviral drug

*

Key Points: 
  • *
    The company revealed its launch plans this week at the 29th European Congress of Clinical Microbiology & Infectious Diseases in Amsterdam.
  • Galileo Pathogen Solution offers the ability to detect antiviral resistance genes, coupled with simultaneous quantitative detection of these viruses comprised of greater than 350 curated viral strains.
  • The Arc Bio Galileo Pathogen Solution enables accurate strain level identification and antimicrobial resistance annotation of virtually all pathogenic microbes present in a primary sample in less than 48 hours.
  • For more information on Arc Bio, its technology and its service offerings visit www.arcbio.com
    *All products are currently for Research Use Only.

IDbyDNA Announces New Scientific Advisory Board Members

Retrieved on: 
수요일, 4월 10, 2019
Technology, Software, Health, Biotechnology, Genetics, Hospitals, Infectious diseases, Research, Science, Branches of biology, Biology, Bioinformatics, Genomics, Microbiology, Environmental microbiology, Microorganism, Metagenomics, Medical microbiology

IDbyDNA , a metagenomics technology company setting a new standard for the identification and understanding of microorganisms and their role in human health, today announced the appointment of two new members to its Scientific Advisory Board (SAB).

Key Points: 
  • IDbyDNA , a metagenomics technology company setting a new standard for the identification and understanding of microorganisms and their role in human health, today announced the appointment of two new members to its Scientific Advisory Board (SAB).
  • On behalf of all of us at IDbyDNA, I would like to welcome Dr. Eddy Rubin and Dr. Alan T. Wright to our Scientific Advisory Board, said Guochun Liao, Ph.D., IDbyDNAs Founder, President & Chief Executive Officer.
  • The IDbyDNA SAB is comprised of world leaders in infectious diseases (ID), human and microbial genomics, medical microbiology and bioinformatics.
  • IDbyDNA has developed transformative metagenomics technology to simultaneously profile tens of thousands of microorganisms and pathogens in any sample.

Cidara Therapeutics Announces Multiple Presentations at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

Retrieved on: 
화요일, 3월 26, 2019
Health, Biotechnology, Clinical trials, Infectious diseases, Pharmaceutical, Medical specialties, Branches of biology, Medicine, RTT, Virology, Influenza, Vaccine, Infection, Antiviral drug, Medical microbiology

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced a total of 10 upcoming presentations summarizing data on the companys lead antifungal rezafungin and its Cloudbreak antiviral program at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).

Key Points: 
  • Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced a total of 10 upcoming presentations summarizing data on the companys lead antifungal rezafungin and its Cloudbreak antiviral program at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID).
  • Our AVCs offer a fundamentally novel approach designed to provide seasonal protection from influenza, including those strains not covered by seasonal vaccines.
  • Because of their unique dual mechanism of action, our AVCs are also, unlike vaccines, expected to protect patients with compromised immune systems.
  • ECCMID convenes leading experts from around the world to present and discuss the latest research findings in infectious diseases, infection control and clinical microbiology.

Dr. Stephen Brecher Joins First Light Diagnostics Clinical Advisory Board

Retrieved on: 
수요일, 3월 13, 2019
Branches of biology, Medical specialties, Medicine, Healthcare-associated infections, Antibiotic-resistant bacteria, Gram-positive bacteria, RTT, Antimicrobial resistance, Clostridioides difficile, Medical microbiology, Infection

CHELMSFORD, Mass., March 13, 2019 /PRNewswire/ -- First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Stephen Brecher to the company's world-class, international Clinical Advisory Board.

Key Points: 
  • CHELMSFORD, Mass., March 13, 2019 /PRNewswire/ -- First Light Diagnostics, a developer of breakthrough automated products for rapid, sensitive, and cost-effective diagnosis of life-threatening, antibiotic-resistant infections, today announced the addition of Dr. Stephen Brecher to the company's world-class, international Clinical Advisory Board.
  • "Stephen is an internationally recognized expert for his work with C. difficile infections and antibiotic resistance," said David Macdonald, CEO of First Light Diagnostics.
  • Also known as the "Chief of Staph," Dr. Brecher has been practicing clinical microbiology for 50 years.
  • "I was excited to be invited to participate as part of the First Light Diagnostics Clinical Advisory Board," said Dr. Brecher.